Moderna Merck Announce 5-Year Data for Intismeran Autogene in . . . Moderna Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA® (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III IV Melanoma Following Complete Resection Save January 20, 2026 6:00 am EST
Moderna Merck Announce 5-Year Data for Intismeran Autogene in . . . "Now with five years of follow-up data, today's results highlight the potential of a prolonged benefit of the intismeran autogene and KEYTRUDA combination in patients with resected high-risk melanoma," said Kyle Holen, M D , Moderna's Senior Vice President and Head of Development, Oncology and Therapeutics "We continue to invest in our platform in oncology because of encouraging outcomes like
RFS Benefit Sustained at 5 Years for Intismeran Autogene in Melanoma REFERENCES 1 Moderna Merck announce 5-year data for intismeran autogene in combination with Keytruda (pembrolizumab) demonstrated sustained improvement in the primary endpoint of recurrence-free survival in patients with high-risk stage III IV melanoma following complete resection News release Merck January 20, 2026
Moderna Merck Announce 5-Year Data for Intismeran Autogene in . . . Read Press Release for Moderna (MRNA) published on Jan 20, 2026 - Moderna Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III IV Melanoma Following Complete Resection
Moderna and Merck Report 5-Year Data on Intismeran Autogene with KEYTRUDA Intismeran autogene with KEYTRUDA reduced recurrence or death risk by 49% in high-risk melanoma Eight Phase 2 and 3 trials are ongoing for various tumor types Further data will be presented at a future medical conference
Merck Moderna’s Personalized mRNA Vaccine Sustains 49% Risk Reduction . . . CAMBRIDGE, Mass RAHWAY, N J — January 20, 2026— In a landmark update for the oncology sector, Moderna and Merck (known as MSD outside the U S ) have released five-year follow-up data from the Phase IIb KEYNOTE-942 trial The results show that the combination of intismeran autogene (mRNA-4157 V940) and Keytruda continued to reduce the risk of recurrence or death by 49% (HR=0 51) in
mRNA Vaccine Pembrolizumab Shows Sustained 5-Year RFS in High-Risk . . . References Moderna Merck Announce 5-year data for intismeran autogene in combination with KEYTRUDA® (pembrolizumab) demonstrated sustained improvement in the primary endpoint of recurrence-free survival in patients with high-risk stage III IV melanoma following complete resection News release Merck January 20, 2026